Overall, we concluded that the current study was underpowered to adequately investigate associations between CYP2C19 (calculated power range: 0.06–0.13) and CYP2D6 (calculated power range: 0.27–0.29) metabolizer status and switching/discontinuing AD treatment. This evidence concerns the gene CYP2C19 and Alzheimer disease.